Literature DB >> 15669881

Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.

Katherine A Lyseng-Williamson1, Neil A Reynolds, Greg L Plosker.   

Abstract

Tenofovir disoproxil fumarate (tenofovir DF; Viread), an ester prodrug of the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir, is indicated in combination with other antiretroviral agents in the treatment of HIV infection. As a component of an antiretroviral regimen, oral tenofovir DF 300 mg once daily effectively reduces viral load in patients with HIV infection who are treatment-experienced with baseline NRTI resistance mutations or treatment-naive. Tenofovir DF provides a simple and convenient once-daily dosage regimen, and is generally well tolerated and able to produce sustained suppression of viral replication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15669881     DOI: 10.2165/00003495-200565030-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  44 in total

1.  Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism.

Authors:  J Van Gelder; S Deferme; P Annaert; L Naesens; E De Clercq; G Van den Mooter; R Kinget; P Augustijns
Journal:  Drug Metab Dispos       Date:  2000-12       Impact factor: 3.922

2.  Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.

Authors:  M D Miller; N A Margot; K Hertogs; B Larder; V Miller
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2001 Apr-Jul       Impact factor: 1.381

3.  Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA.

Authors:  B L Robbins; R V Srinivas; C Kim; N Bischofberger; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

4.  Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.

Authors:  Robert T Schooley; Peter Ruane; Robert A Myers; Gildon Beall; Harry Lampiris; Daniel Berger; Shan-Shan Chen; Michael D Miller; Erica Isaacson; Andrew K Cheng
Journal:  AIDS       Date:  2002-06-14       Impact factor: 4.177

5.  Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.

Authors:  Eugènia Negredo; José Moltó; José Antonio Muñoz-Moreno; Enric Pedrol; Esteve Ribera; Pompeyo Viciana; M José Galindos; Celia Miralles; David Burger; Carmina Rodriguez Fumaz; Jordi Puig; Sílvia Gel; Eva Rodríguez; Sebastià Videla; Lidia Ruiz; Bonaventura Clotet
Journal:  Antivir Ther       Date:  2004-06

6.  Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.

Authors:  Michael D Miller; Nicolas Margot; Biao Lu; Lijie Zhong; Shan-Shan Chen; Andrew Cheng; Michael Wulfsohn
Journal:  J Infect Dis       Date:  2004-02-10       Impact factor: 5.226

7.  Resistance issues with new nucleoside/nucleotide backbone options.

Authors:  Mark A Wainberg; Dan Turner
Journal:  J Acquir Immune Defic Syndr       Date:  2004-09-01       Impact factor: 3.731

8.  Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.

Authors:  Steven Coca; Mark A Perazella
Journal:  Am J Med Sci       Date:  2002-12       Impact factor: 2.378

9.  Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.

Authors:  Rohan Hazra; Frank M Balis; Antonella N Tullio; Ellen DeCarlo; Carol J Worrell; Seth M Steinberg; John F Flaherty; Kitty Yale; Marianne Poblenz; Brian P Kearney; Lijie Zhong; Dion F Coakley; Stephane Blanche; Jean Louis Bresson; Judith A Zuckerman; Steven L Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.

Authors:  M A Wainberg; M D Miller; Y Quan; H Salomon; A S Mulato; P D Lamy; N A Margot; K E Anton; J M Cherrington
Journal:  Antivir Ther       Date:  1999
View more
  21 in total

1.  In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.

Authors:  Francesc Vidal; Joan Carles Domingo; Jordi Guallar; Maria Saumoy; Begoña Cordobilla; Rainel Sánchez de la Rosa; Marta Giralt; Maria Luisa Alvarez; Miguel López-Dupla; Ferran Torres; Francesc Villarroya; Tomas Cihlar; Pere Domingo
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

2.  Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?

Authors:  Natella Y Rakhmanina; John N van den Anker; Steven J Soldin; Ron H van Schaik; Nick Mordwinkin; Michael N Neely
Journal:  Ther Drug Monit       Date:  2010-06       Impact factor: 3.681

3.  Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.

Authors:  Jeremiah D Momper; Brookie M Best; Jiajia Wang; Edmund V Capparelli; Alice Stek; Emily Barr; Martina L Badell; Edward P Acosta; Murli Purswani; Elizabeth Smith; Nahida Chakhtoura; Kyunghun Park; Sandra Burchett; David E Shapiro; Mark Mirochnick
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

4.  Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057.

Authors:  Luiz Eduardo Osorio; Maria Ines Boechat; Mark Mirochnick; Newton Kumwenda; Regis Kreitchmann; Lynda Emel; Jorge Pinto; Esau Joao; Breno Santos; Molly Swenson; Kathleen George; Paul Sato; Lynne Mofenson; Karin Nielsen-Saines
Journal:  Pediatr Infect Dis J       Date:  2017-02       Impact factor: 2.129

Review 5.  Microbicides in the prevention of HIV infection: current status and future directions.

Authors:  Jeremy Nuttall
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

Review 6.  Emtricitabine: a review of its use in the management of HIV infection.

Authors:  James E Frampton; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet.

Authors:  James E Frampton; Katherine F Croom
Journal:  Drugs       Date:  2006       Impact factor: 9.546

8.  Tenofovir renal toxicity targets mitochondria of renal proximal tubules.

Authors:  James J Kohler; Seyed H Hosseini; Amy Hoying-Brandt; Elgin Green; David M Johnson; Rodney Russ; Dung Tran; C Michael Raper; Robert Santoianni; William Lewis
Journal:  Lab Invest       Date:  2009-03-09       Impact factor: 5.662

Review 9.  Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.

Authors:  Sarah L Greig; Emma D Deeks
Journal:  Drugs       Date:  2016-06       Impact factor: 9.546

Review 10.  Tenofovir disoproxil fumarate: in chronic hepatitis B.

Authors:  Caroline M Perry; Dene Simpson
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.